Innovative Technology Cullgen's proprietary uSMITE™ platform presents a unique opportunity to target undruggable brain disease proteins, offering potential therapeutic solutions in areas where current treatments fall short.

Strategic Partnerships Recent collaborations with industry leaders like Astellas Pharma and AstraZeneca demonstrate Cullgen's growing influence and open avenues for joint development, licensing, or co-marketing agreements.

Funding Momentum With over 66 million USD in funding and multiple financing rounds including a 40 million USD Series C, Cullgen has the financial backing to expand research capabilities and accelerate product pipeline commercialization.

Market Expansion Cullgen's focus on protein degradation technology positions it well to serve the global biotech and pharma markets, particularly companies seeking novel chemical entities for complex intracellular targets.

Industry Alignment Competitively positioned alongside large biotech firms with a niche in targeted protein degradation, Cullgen offers tailored solutions that can complement and enhance the portfolios of major pharmaceutical companies seeking innovative therapeutics.